Skip to content
Search our Site
Search our site
Search our site
My PD Journey
About the EPDA
Political affairs and policy
Resources and publications
All research papers
Search research papers
Medication research papers
A study on the protective role of doxycycline upon dopaminergic neuron of LPS-PD rat model rat
CONCLUSIONS: Doxycycline can inhibit degeneration of LPS-induced dopaminergic neurons. Its neuroprotective function is achieved by downregulating the microglia MHC II expression.
06 October 2015
Effects of rotigotine transdermal patch in patients with Parkinson's presenting with non-motor symptoms results of a double ..
Conclusions: Rotigotine improvement in the multi-domain NMSS total score was not superior to placebo. A different sensitivity of individual NMSS domains to dopaminergic therapy and a large placebo effect may have contributed to these findings.
01 October 2015
Pharmacogenetic stimulation of cholinergic pedunculopontine neurons reverses motor deficits in rat model of Parkinson's disease
Authors show that transient activation of the remaining PPTg cholinergic neurons in the lactacystin rat model of PD, via peripheral administration of the cognate DREADD ligand, clozapine-N-oxide (CNO), dramatically improved motor symptoms, as was assessed by behavioral tests that measured postural instability, gait, sensorimotor integration, forelimb akinesia and general motor activity.
23 September 2015
Mitochondrial Quality Control via PGC1α-TFEB Signaling Pathway Compromised by Parkin Q311X Mutation But Restored by Rapamycin
Studies in human iPSC-derived neurons demonstrate that TFEB induction can restore mitochondrial function and cell viability in a mitochondrially compromised human cell model. Based on these data, authors propose that the parkin Q311X mutation impacts on mitochondrial quality control via PARIS-mediated regulation of PGC1α-TFEB signaling and that this can be independently restored via upregulation of TFEB function.
16 September 2015
Non-ergot dopamine agonists and the risk of heart failure and other adverse cardiovascular reactions in Parkinson's disease
This review will increase our understanding of the cardiac events associated with non-ergot dopamine agonists and will serve to identify knowledge gaps and further research priorities.
03 September 2015
Effect of 24-h continuous rotigotine treatment on stationary & non-stationary locomotion in de novo patients with Parkinson's
The main finding that emerges from the present study is that the dopamine agonist rotigotine can improve various aspects of gait in de novo PD patients.
25 August 2015
A Randomized, Double-Blind, Controlled trial of droxidopa add-on therapy in moderate-to-severe Parkinson's disease
Conclusions: Droxidopa was effective as symptomatic adjunct therapy, improved significantly motor function and activities of daily living, benefited patients with signs of tremor and Stiffness.
21 August 2015
The motor inhibition system in Parkinson's disease with levodopa-induced dyskinesia
Conclusions: The study demonstrated that levodopa intake in dyskinetic patients tends to alter the functioning of some parts of the neural network involved in motor inhibitio
14 August 2015
Physician response to a medication alert system in inpatients with levodopa-treated diseases
Conclusions: Despite successfully identifying instances when dopamine antagonists were prescribed to patients with dopamine-requiring diseases, the alert system modestly affected physician prescribing behavior, highlighting the need for improved education of health care providers.
04 August 2015
Long-term treatment with l-DOPA or pramipexole affects adult neurogenesis and corresponding non-motor behavior in a mouse model
Authors found that l-DOPA and pramipexole can normalize decreased neurogenesis in the hippocampal dentate gyrus and the periglomerular layer of the olfactory bulb caused by a 6-OHDA lesion.
01 August 2015
Back to Top
Add page to PDF basket
Copyright © 2015 EPDA. All Rights Reserved.
Privacy and cookies